Eric Karas - 12 Jun 2026 Form 4 Insider Report for ARS Pharmaceuticals, Inc. (SPRY)

Reporting relationship: Chief Commercial Officer
Issuer ticker: SPRY
Reported as of: 12 Jun 2026
Net transaction value: -$250,000
SEC form: 4
Accepted by SEC: 12 Jun 2026, 20:06:14 UTC
Prior SEC filing: 05 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Kathleen Scott, Attorney-in-Fact

Key filing fact

Eric Karas filed Form 4 for ARS Pharmaceuticals, Inc. (SPRY) on 12 Jun 2026.

Key facts

This page summarizes Eric Karas's Form 4 filing for ARS Pharmaceuticals, Inc. (SPRY).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 20:06.

Change

Previous filing in this sequence was filed on 05 Jan 2026.
Current net transaction value: -$250,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001951287 Primary reporting owner

Karas Eric

Relationship: Chief Commercial Officer
Address: C/O ARS PHARMACEUTICALS, INC., 11682 EL CAMINO REAL, SUITE 300, SAN DIEGO
Signature: /s/ Kathleen Scott, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SPRY transaction

Common Stock

Options Exercise

Transaction value
Shares: +25,000
Change %: +205%
Price: $1.50^*
Shares after: 37,176
Date: 12 Jun 2026
Ownership: Direct
Footnotes: F1

SPRY transaction

Common Stock

Sale

Transaction value: $250,000
Shares: -25,000
Change %: -67%
Price: $10.00
Shares after: 12,176
Date: 12 Jun 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SPRY transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -25,000
Change %: -4.6%
Price: $0.000000^*
Shares after: 519,588
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $1.50
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

Includes 1,861 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2025.

Footnote F2

The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2025.

Footnote F3

Immediately exercisable.